Great Bay Bio Showcases World's First Intelligent Biologics Development Ecosystem at T20 Conference

▲ Dr. Chen Liang attended the "Cross-disciplinary Integration Empowering Frontier Drug Development" forum co-organized by StarBridge Venture Capital.

Proxima Ventures is committed to discovering medical innovation technologies with great potential globally, gathering talent and resources, and rapidly applying innovative therapies to clinical practice in China through joint efforts with entrepreneurs. "Cross-integration empowers cutting-edge drug development" is its starting point for investing in the biopharmaceutical track.

▲“Cross-Integration Empowers Frontier Drug Development” Forum Scene

The conference kicked off with a keynote speech by Mr. Sun Xiaolu, Managing Partner of Proxima Ventures, on the theme "Global Collaboration, Innovation Unstoppable." The invited guests, Professor Chen Liangyi from Peking University and Mr. Li Zhe, Managing Partner of Proxima Ventures, delivered keynote speeches respectively, focusing on how interdisciplinary innovative tools and technology platforms upstream of new drug development can empower cutting-edge pharmaceutical R&D.

▲Dr. Chen Liang Delivers a Speech

At this forum, seven representative invested companies of Proxima Ventures, including Great Bay Bio, made impressive appearances. Each founder/entrepreneur introduced the platform value and highlights of their companies. Dr. Chen Liang delivered a speech titled "The World's First Intelligent Biopharmaceutical Development Ecosystem," presenting a one-stop, cross-disciplinary, scientific big data-driven technology platform that is driving revolutionary changes across the entire biopharmaceutical industry.The ecosystem covers the entire process from molecular design to the CMC stage, including antibody sequence generation, high-activity protein sequence generation, one-stop medium optimization, cell line screening, etc., helping customers develop products faster and better.

▲The world's first intelligent biopharmaceutical development ecosystem

During the industry dialogue session, special invited guests, industry experts, investment experts, and entrepreneurs shared their insights on the topic of "The Potential and Boundaries of the Upstream New Drug Industry."Dr. Chen Liang discussed the applications of automation, artificial intelligence, and big data in drug development, emphasizing the potential of these cross-disciplinary tools in drug discovery and development, particularly in reducing repetitive tasks and blind selection work.

▲ Dr. Chen Liang Attends Industry Dialogue

Proxima Venture successfully co-hosted the Cross-disciplinary Integration Empowering Frontier Drug Development Forum, incorporating perspectives from academia, industry, and investment sectors to inspire innovative thinking in industrial integration and jointly explore the role of cross-disciplinary tools in enhancing the efficiency of new drug development.GBB is willing to explore the hotspots and future trends in new drug development with colleagues in the industry, and work together to pave the way for breakthrough progress in human health.